Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan 1;11(6):1315-1324.
doi: 10.7150/jca.39044. eCollection 2020.

MicroRNA-183 in Cancer Progression

Dingren Cao  1 , Min Di  2 , Jingjie Liang  1 , Shuang Shi  1 , Qiang Tan  1 , Zhengguang Wang  1
Affiliations
Review

MicroRNA-183 in Cancer Progression

Dingren Cao et al. J Cancer. .

Abstract

MicroRNA-183(miR-183) is abnormally expressed in many kinds of tumors. It participates in the initiation and development of tumors. There are many pathways regulate the expression of miR-183. The action mechanism of miR-183 in cancer is very extensive, and contradictory conclusions are often drawn. It was upregulated in 18 kinds of cancer, downregulated in 6 kinds of cancer. In addition, there are seven types of cancer, both upregulated and downregulated reports can be found. Evidence showed that miR-183 can not only directly play the role of oncogene or antioncogene, but also regulate the expression of other oncogene or antioncogene in different cancer types. In this review, we discuss the regulator of miR-183 and summarized the expression of miR-183 in different cancers. We also counted the target genes of miR-183 and the functional roles they play. Furthermore, we focused on the roles of miR-183 in cell migration, cell invasion, epithelial-mesenchymal transition (EMT) and microangiogenesis, which play the most important roles in cancer processes. It sheds light on the likely reasons why miR-183 plays different roles in various cancers. In addition, miR-183 and its downstream effectors have the potential to be promising prognostic markers and therapeutic targets in cancer.

Keywords: EMT; cancer progression; metastasis; microRNA-183; microangiogenesis.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

Figures

Figure 1
Figure 1
Binding site location of transcriptional regulators. (A) Research in human genome: binding sites of transcriptional factor in upstream of miR-183. (B) Research in mouse genome: binding sites of transcriptional factor in upstream of miR-183.
Figure 2
Figure 2
Mechanisms of miR-183 in cancer progression at cellular and molecular level.
See this image and copyright information in PMC

References

    1. Taylor MA, Schiemann WP. Therapeutic opportunities for targeting microRNAs in cancer. Mol Cell Ther. 2014;2:1–13. - PMC - PubMed
    1. Kozomara A, Birgaoanu M, Griffiths-Jones S. MiRBase: from microRNA sequences to function. Nucleic Acids Res. 2019;47(D1):D155–62. - PMC - PubMed
    1. Bartel DP. MicroRNAs: Target recognition and regulatory functions. Cell. 2009;136:215–33. - PMC - PubMed
    1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97. - PubMed
    1. Lagos-quintana M, Rauhut R, Meyer J. et al. New microRNAs from mouse and human. RNA. 2003;9:175–9. - PMC - PubMed